Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Making LDL Matter Again: Addressing Clinical, Patient, and Payer Barriers in ASCVD Management : Episode 11
PCSK9 Inhibitor Underuse
Panelists discuss how PCSK9 inhibitors remain underused due to access, cost, and adherence barriers.
EP: 1.Understanding the Current State of LDL-C Goal Attainment and Barriers to Adequate Control in Hyperlipidemia
EP: 2.Challenges with Undertreatment in Hyperlipidemia and Opportunities to Address this Gap
EP: 3.Pharmacy-Driven Challenges
EP: 4.Real-World Insights and PROMPT-LIPID
EP: 5.Social Determinants of Health
EP: 6.The 2013 Guideline Shift
EP: 7.Unintended Consequences of Metric Changes
EP: 8.Reinstating LDL-C Targets
EP: 9.International LDL Thresholds
EP: 10.Nonstatin Therapy Decisions
Now Viewing
EP: 11.PCSK9 Inhibitor Underuse
EP: 12.Payer and Prior Authorization Barriers
EP: 13.Adherence and Persistence
EP: 14.Cumulative LDL-C Exposure
EP: 15.Economic Burden and Systemwide Strategies
Panelists discuss how PCSK9 inhibitors remain underutilized despite their strong efficacy and safety record. The main barriers are cost, prior authorization requirements, and patient hesitancy with injectable formats.
They note that even eligible high-risk patients often abandon therapy due to administrative complexity or affordability.
Panelists call for streamlined access pathways and education to ensure these life-saving agents reach appropriate patients.
Related Videos
Related Content
